Surf Bio

Surf Bio is a private, preclinical-stage biotech leveraging its proprietary Surf SnapShot™ platform to revolutionize the subcutaneous delivery of biologics. Its core innovation is a polymer-based excipient that stabilizes proteins at unprecedented concentrations (>600 mg/mL), enabling high-dose, at-home administration of drugs that currently require clinic-based IV infusions. With a seasoned leadership team from Bigfoot Biomedical and Stanford, and backed by partnerships with major pharma companies, Surf Bio aims to significantly improve patient access and convenience across multiple chronic disease areas.

Surf SnapShot™: A proprietary polymer-based excipient platform that enables ultra-high concentration (>600 mg/mL), stable, low-viscosity formulations of monoclonal antibodies and biologics for rapid, high-dose subcutaneous injection via standard autoinjector.

Surf Bio competes with other drug delivery and formulation technology companies like Halozyme (ENHANZE®), Enable Injections, and several private firms. Differentiation lies in the specific polymer technology enabling extreme concentration. The competitive threat also includes internal formulation efforts by large biopharma companies themselves.